What the price cut does and where limits remain Novo Nordisk has said it will cut the list prices of its leading GLP‑1 drugs in the United States by up to 50% beginning in 2027. The company frames the move as a way to expand access to widely prescribed diabet…
Novo Nordisk has said it will cut the list prices of its leading GLP1 drugs in the United States by up to 50% beginning in 2027. The company frames the move as a way to expand access to widely prescr… [+1861 chars]
